NEWTON, Mass.– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through targeted modulation of cytotoxic T cells, has appointed George Eldridge as chief financial officer.
Eldridge brings more than 30 years of financial leadership across the biotechnology sector, including expertise in fundraising, public offerings, mergers and acquisitions, and operational finance. Most recently, he was CFO of Aerovate Therapeutics, where he guided the company through its 2021 initial public offering and its 2025 reverse merger with Jade Biosciences. He has also held CFO roles at Proteon Therapeutics, Targanta Therapeutics, Therion Biologics, Curis (formerly Ontogeny), and Boston Life Sciences, in addition to serving as a consultant to early-stage biotech companies.
“George brings industry-leading financial expertise that will be essential to Abcuro as we prepare for a pivotal clinical data readout for our lead asset, ulviprubart,” said Alex Martin, CEO of Abcuro. “We are delighted to further strengthen our leadership team with George’s appointment and look forward to working with him to build on our strong financial position to advance ulviprubart.”
Eldridge, who holds an MBA from the University of Chicago Booth School of Business and a BA from Dartmouth College, said he is eager to join the company at a critical juncture. “I am honored to join Abcuro and look forward to working closely with the leadership team to deliver on our mission to develop potentially life-transforming treatments for patients with devastating diseases like IBM,” he said. “This is also a pivotal time for Abcuro, and we will continue to focus on execution as we approach key milestones including initial data readout from the ongoing MUSCLE study next year.”
